- Home
- ADSE vs ESPR Comparison
ADSE vs ESPR Comparison
Compare ADSE & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | ESPR |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 660.1M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | ADSE | ESPR |
|---|---|---|
| Price | $12.27 | $3.67 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.86 |
| AVG Volume (30 Days) | 26.9K | ★ 7.5M |
| Earning Date | 12-23-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $53,275,396.00 | ★ $303,802,000.00 |
| Revenue This Year | $219.58 | $18.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2.83 |
| 52 Week Low | $7.89 | $0.69 |
| 52 Week High | $16.35 | $4.03 |
Technical Indicators
Market Signals| Indicator | ADSE | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 63.47 |
| Support Level | $9.76 | $2.66 |
| Resistance Level | $10.68 | $4.03 |
| Average True Range (ATR) | 0.68 | 0.24 |
| MACD | 0.24 | 0.08 |
| Stochastic Oscillator | 89.47 | 72.63 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.